Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. BIIB
BIIB logo

BIIB

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

BIIB News

Biotech Sector Sees FDA Approvals and Layoffs

20h agoNASDAQ.COM

U.S. Stock Futures Rise as Investors Eye Four Key Stocks

1d agoseekingalpha

Biogen Acquires RayThera to Expand Immunology Pipeline

2d agoseekingalpha

Biogen Acquires RayThera for Up to $1 Billion

2d agoNASDAQ.COM

Biogen Acquires RayThera to Enhance Immunology Pipeline

2d agostocktwits

Biogen Acquires RayThera for Up to $1 Billion

2d agoNewsfilter

Pomerantz LLP Investigates Biogen for Securities Fraud

3d agoGlobenewswire

Biogen Under Investigation for Securities Fraud Claims

Jun 11 2026PRnewswire

Biogen Faces Investigation Over Securities Violations

Jun 10 2026Globenewswire

Biogen Under Investigation for Potential Securities Fraud

Jun 09 2026Globenewswire

Latest Wall Street Ratings Overview

Jun 08 2026CNBC

Revolution Medicines Achieves Strong Phase 3 Clinical Trial Results

Jun 05 2026NASDAQ.COM

Revolution Medicines Stock Soars 285% Amid Clinical Progress

Jun 05 2026Fool

Pharmaceutical Giants Accelerate Acquisitions to Offset Patent Cliffs

Jun 05 2026stocktwits

Biogen's Salanersen Receives FDA Breakthrough Therapy Designation

Jun 04 2026NASDAQ.COM

Pomerantz LLP Investigates Biogen for Securities Fraud

Jun 04 2026PRnewswire